Does Selank bind the GABA receptor?

Reported work describes effects on GABA-A receptor expression rather than direct binding to the receptor.

Is that the same as how benzodiazepines work?

No. Benzodiazepines are direct positive allosteric modulators at the GABA-A receptor. An expression-level effect is a different pharmacological category operating on a slower timescale.

Are Selank's reported mechanisms connected to each other?

Not established. Enkephalinase inhibition, GABAergic effects and BDNF expression are separately reported observations rather than one confirmed pathway.

Selank (Tuftsin Analogue)

Selank and GABAergic Signalling

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Reported work describes Selank influencing GABAergic signalling through changes in GABA-A receptor expression in the hippocampus, rather than by binding the receptor itself. That is mechanistically distinct from benzodiazepines, which are direct positive allosteric modulators at the GABA-A receptor.

Key facts

System: GABAergic (inhibitory)
Reported effect: Altered GABA-A receptor expression
Region cited: Hippocampus
Direct receptor binding: Not described
Benzodiazepine mechanism: Direct allosteric modulation
Model organism: Rodent

How GABA-A signalling normally works

GABA is the principal inhibitory neurotransmitter in the mammalian brain. The GABA-A receptor is a ligand-gated chloride channel: when GABA binds, chloride enters and the neuron becomes less likely to fire. Its activity can be modulated by compounds binding at sites distinct from the GABA site itself — this is what positive allosteric modulation means.

What benzodiazepines do

Benzodiazepines bind a specific allosteric site on the GABA-A receptor and increase the receptor's response to GABA. They do not open the channel themselves; they amplify the effect of GABA when it is present. Because that amplification is immediate and dose-dependent, the pharmacology is fast, powerful and associated with tolerance on sustained exposure.

Research material referenced

Selank 10mg — third-party HPLC tested

View — £24.99

What is reported for Selank

The published description is different in kind. Selank has been reported to influence inhibitory signalling in the hippocampus through changes in GABA-A receptor expression rather than by binding the receptor. An expression-level effect operates on a slower timescale than allosteric modulation — receptor protein has to be made — and it is a distinct pharmacological category, not a variation on the same theme.

Why the distinction is worth stating carefully

It is tempting to translate 'different mechanism from benzodiazepines' into a claim about comparative safety or dependence. That is not a claim the mechanism supports on its own, and it is not one that can be made about material supplied for laboratory research. What can be said accurately is narrower: the reported mechanism is expression-level rather than direct allosteric modulation, and those are different pharmacological categories.

How it sits alongside the other reported activities

GABAergic effects, enkephalinase inhibition and BDNF expression are three separately reported activities. Whether they are causally connected, or which is primary, is not established by the published work. Treating them as one unified mechanism overstates what has been shown; the literature describes several observations rather than one confirmed pathway.

Extended research context

The Selank (Tuftsin Analogue) deep dive

Deep dive: preserving a signal rather than supplying one

Selank's most specifically characterised activity is not receptor binding. Work published in the Bulletin of Experimental Biology and Medicine in 2001 and 2002 reported that it inhibits enkephalin-degrading enzymes, measured directly on plasma enkephalinase activity, thereby extending the half-life of endogenous enkephalins rather than acting at opioid receptors itself. That distinction is routinely muddled and it matters: an agonist activates the receptor wherever the drug reaches, at whatever concentration is given, while a degradation inhibitor only lets the ligand the body is already releasing persist longer. The effect is bounded by endogenous release and occurs only where that release happens. The same logic underlies DPP-4 inhibitors in the incretin field, which prolong native GLP-1 rather than supplying an analogue - and instructively, that class produces much smaller effects than the receptor agonists do.

Deep dive: what the sequence does and does not contain

TKPRPGP is unusual among research peptides for what is absent from it. There is no cysteine, so no disulfide bonds form or scramble and no reducing agent is needed. There is no methionine, so the thioether oxidation that adds 16 Da and dominates handling guidance for MOTS-c and Semax does not apply. There is no asparagine or glutamine either, ruling out deamidation. What remains is straightforward hydrolysis, and three prolines in seven residues resist even enzymatic cleavage well, because proline locks the backbone rotation peptidases require. One practical cost of that composition: no aromatic residues means almost no absorbance at 280 nm, so the standard spectrophotometric quantification method does not work on it.

Deep dive: reading a two-literature evidence base

PubMed indexes roughly 135 Selank records against about 690 for its parent peptide tuftsin - an inversion worth noticing, since most designed analogues eventually outgrow the parent they replaced. Most of the tuftsin literature is immunological and predates Selank entirely, so it is not evidence about Selank. Within Selank's own record the split is the same one Semax shows: mechanistic work in internationally indexed journals, assessable directly; clinical work concentrated in Russian-language publications, indexed by translated title and often without accessible English full text. That is evidence which is hard to verify independently, which is not the same as evidence that is absent, and not the same as evidence that is established.

Research applications

▸Enkephalin and enkephalinase pathway research
▸GABAergic receptor expression studies in rodent models
▸BDNF expression research, including intranasal administration routes
▸Comparative work on proline-stabilised peptide design
▸Tuftsin and immunopeptide structure-activity research

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓No reducing agent needed — the sequence contains no cysteine
✓No methionine oxidation to expect; a +16 Da satellite warrants explanation
✓Do not rely on 280 nm absorbance — there are no aromatic residues
✓Introduce diluent gently against the vial wall; swirl rather than shake
✓Aliquot to avoid repeated freeze-thaw cycles

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Describing Selank as an opioid or opioid agonist

Fix: Reported work describes inhibition of enkephalin-degrading enzymes, not receptor binding. It preserves endogenous enkephalins rather than supplying an agonist.

✗ Treating the benzodiazepine contrast as a safety claim

Fix: The mechanistic difference is real — expression-level rather than direct allosteric modulation — but it supports no comparative claim about safety or dependence.

✗ Citing tuftsin literature as evidence about Selank

Fix: Tuftsin has roughly five times more papers, most of them immunological and predating Selank. They are different compounds.

✗ Reading a BDNF expression change as a demonstrated outcome

Fix: The work measured expression in rat hippocampus. Expression is upstream of function and upstream again of any clinical claim.

✗ Treating Russian registration as equivalent to MHRA approval

Fix: Authorisations are jurisdictional and do not transfer. Selank has never been assessed by the MHRA, EMA or FDA.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Does Selank bind the GABA receptor?: Reported work describes effects on GABA-A receptor expression rather than direct binding to the receptor.
Is that the same as how benzodiazepines work?: No. Benzodiazepines are direct positive allosteric modulators at the GABA-A receptor. An expression-level effect is a different pharmacological category operating on a slower timescale.
Are Selank's reported mechanisms connected to each other?: Not established. Enkephalinase inhibition, GABAergic effects and BDNF expression are separately reported observations rather than one confirmed pathway.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Selank (Tuftsin Analogue) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum